Filtered By:
Cancer: Liver Cancer
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 31222 results found since Jan 2013.
Pharmacokinetics and Biodistribution of Recently-Developed siRNA Nanomedicines.
Abstract
Small interfering RNA (siRNA) is a promising drug candidate, expected to have broad therapeutic potentials toward various diseases including viral infections and cancer. With recent advances in bioconjugate chemistry and carrier technology, several siRNA-based drugs have advanced to clinical trials. However, most cases address local applications or diseases in the filtering organs, reflecting remaining challenges in systemic delivery of siRNA. The difficulty in siRNA delivery is in large part due to poor circulation stability and unfavorable pharmacokinetics and biodistribution profiles of siRNA. This rev...
Source: Advanced Drug Delivery Reviews - December 10, 2015 Category: Drugs & Pharmacology Authors: Park J, Park J, Pei Y, Xu J, Yeo Y Tags: Adv Drug Deliv Rev Source Type: research
Lentivirus vectors construction of SiRNA targeting interference GPC3 gene and its biological effects on liver cancer cell lines Huh-7
Conclusions The targeted GPC3 siRNA can effectively inhibit the expression of GPC3.
Source: Asian Pacific Journal of Tropical Medicine - October 12, 2014 Category: Tropical Medicine Source Type: research
Inhibition of IL-8-mediated endothelial adhesion, VSMCs proliferation and migration by siRNA-TMEM98 suggests TMEM98's emerging role in atherosclerosis.
Authors: Lv G, Zhu H, Li C, Wang J, Zhao D, Li S, Ma L, Sun G, Li F, Zhao Y, Gao Y
Abstract
Transmembrane protein 98 (TMEM98), known as a novel gene related to lung cancer, hepatocellular carcinoma, differentiation of T helper 1 cells and normal eye development, has no defined role reported in terms of atherosclerosis (AS). To investigate the potential involvement of TMEM98 during AS processes, its obvious secretion and expression has been initially characterized in hyperlipidemia patients' serum and AS mice's serum respectively. We then explored the possible role of TMEM98 in the pathogenesis of AS in vitro. IL-8,...
Source: Oncotarget - November 22, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy.
Abstract
Graphene oxide (GO) has attracted huge attention in biomedical field in recent years. However, limited attempts have been invested in utilizing GO on active targeted delivery for gene therapy in liver cancer treatments. Glycyrrhetinic acid (GA) has been reported to be widely used as a targeting ligand to functionalize nanomaterials to treat hepatocellular carcinoma. In this article, GA is employed as a liver targeting ligand to construct GA, polyethylene glycol (PEG), polyamidoamine dendrimer (Dendrimer) and nano-graphene oxide (NGO) conjugate (GA-PEG-NGO-Dendrimer, GPND) for siRNA delivery for the first ...
Source: European Journal of Pharmaceutical Sciences - August 21, 2019 Category: Drugs & Pharmacology Authors: Qu Y, Sun F, He F, Yu C, Lv J, Zhang Q, Liang D, Yu C, Wang J, Zhang X, Xu A, Wu J Tags: Eur J Pharm Sci Source Type: research
Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
Multiple targets RNAi strategy is a preferred way to treat multigenic diseases, especially cancers. In the study, multi-target siRNAs were designed to inhibit NET-1, EMS1 and VEGF genes in hepatocellular carcinoma (HCC) cells. And multi-target siRNAs showed better silencing effects on NET-1, EMS1 and VEGF, compared with single target siRNA. Moreover, multi-target siRNA showed greater suppression effects on proliferation, migration, invasion, angiogenesis and induced apoptosis in HCC cells. The results suggested that multi-target siRNA might be a preferred strategy for cancer therapy and NET-1, EMS1 and VEGF could be effect...
Source: Journal of Cancer - June 26, 2016 Category: Cancer & Oncology Authors: Tiejun Li, Yuwen Xue, Guilan Wang, Tingting Gu, Yunlong Li, York Yuanyuan Zhu, Li Chen Tags: Research Paper Source Type: research
Expression of lncRNA MSC-AS1 in hepatocellular carcinoma cell lines and its effect on proliferation, apoptosis, and migration
CONCLUSION: MSC-AS1 was upregulated in HCC cells, and the downregulation of MSC-AS1 could inhibit cell proliferation, migration, and invasion and promote apoptosis of HCC cells.PMID:33625998 | PMC:PMC7928261 | DOI:10.5152/tjg.2020.19485
Source: The Turkish Journal of Gastroenterology - February 24, 2021 Category: Gastroenterology Authors: Xiaoni Kou Jiang Zhu Xinke Xie Mingxia Hao Yingren Zhao Source Type: research
